Efficacy of a new method of family planning-the Standard Days Method

合集下载

2018年2月10日雅思阅读考情回顾

2018年2月10日雅思阅读考情回顾

2018年2月10日雅思阅读考情回顾
一、考试时间:2018年2月10日(周六)
二、考试概述:
本次考试三篇阅读都比较生僻,没有出现经典阅读文章。

第一篇The history of lighting,是照明工具的发展历史。

此题为2016年2月20日旧题,此类型题在剑桥真题集中层出不穷,比如剑八第一套第一篇A Choronicle of Timekeeping和剑五第二套第一篇的Bakelite - The Birth of Modern Plastics都可以作为参考。

第二篇Biotechnology’s third wave,介绍生物科技,初步认定为阅读新题。

第三篇疑似也是2016年2月20日旧题,题目为Rating women leader,介绍女性领导人与男性的区别。

此类文章在真题集中收录很少,需要通过其他真题库来补充。

三、文章简介
Passage 1: The history of lighting,照明的历史。

Passage 2: Biotechnology’s third wave,生物科技第三波
Passage 3: Rating women leader,女性领导者
四、篇章分析:。

健脾温阳凝胶剂脐疗治疗脾胃虚弱型慢性腹泻的疗效及机制:一项临床随机对照试验

健脾温阳凝胶剂脐疗治疗脾胃虚弱型慢性腹泻的疗效及机制:一项临床随机对照试验

参考文献:[1]Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2021[J ].CAA Cancer J Clinicians,2021,71(1):7-33.[2]郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J ].中华肿瘤杂志,2019,41(1):19-28.[3]Parmar A,Richardson M,Coyte PC,et al.A cost-utility analysis ofatezolizumab in the second-line treatment of patients with metastatic bladder cancer [J ].Curr Oncol,2020,27(4):e386-e394.[4]Huang QZ,Wu X,Wang ZM,et al.The primordial differentiation oftumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1blockade in draining lymph nodes [J ].Cell,2022,185(22):4049-66.e25.[5]Crispen PL,Kusmartsev S.Mechanisms of immune evasion inbladder cancer [J ].Cancer Immunol Immunother,2020,69(1):3-14.[6]Balar A V ,Kamat AM,Kulkarni GS,et al.Pembrolizumabmonotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057):an open-label,single-arm,multicentre,phase 2study [J ].Lancet Oncol,2021,22(7):919-30.[7]Zheng J,Huang J,Zhang L,et al.Drug-loaded microbubble deliverysystem to enhance PD-L1blockade immunotherapy with remodeling immune microenvironment [J ].Biomater Res,2023,27(1):9.[8]李中,黄旭,陈守峰,等.吡非尼酮通过抑制TGF-β1通路和炎症反应预防大鼠尿道损伤后的纤维化及狭窄[J ].南方医科大学学报,2022,42(3):411-7.[9]李杨,杨梅娟,周玉仙,等.吡啡尼酮治疗特发性肺纤维化研究进展[J ].当代医学,2020,26(29):191-4.[10]Qin W,Zou J,Huang YB,et al.Pirfenidone facilitates immuneinfiltration and enhances the antitumor efficacy of PD-L1blockade in mice [J ].OncoImmunology,2020,9(1):1824631.[11]Aboulkheyr Es H,Zhand S,Thiery JP,et al.Pirfenidone reducesimmune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17and TNF-beta [J ].Integr Biol,2020,12(7):188-97.[12]Marwitz S,Turkowski K,Nitschkowski D,et al.The multi-modaleffect of the anti-fibrotic drug pirfenidone on NSCLC [J ].Front Oncol,2019,9:1550.[13]Klement JD,Redd PS,Lu CW,et al.Tumor PD-L1engages myeloidPD-1to suppress type I interferon to impair cytotoxic T lymphocyte recruitment [J ].Cancer Cell,2023,41(3):620-36.e9.[14]Jung M,Rose M,Knuechel R,et al.Characterisation of tumour-immune phenotypes and PD-L1positivity in squamous bladder cancer [J ].BMC Cancer,2023,23(1):113.[15]Galbo PM Jr,Zang XX,Zheng DY .Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis,prognosis,and immunotherapy resistance [J ].Clin Cancer Res,2021,27(9):2636-47.[16]Jiang ZM,Zhang YM,Zhang Y ,et al.Cancer derived exosomesinduce macrophages immunosuppressive polarization to promote bladder cancer progression [J ].Cell Commun Signal,2021,19(1):93.ALTP FD +α-P D-L 1α-PD -L 1P FD C on t r o l302520151050U /LU /L140120100806040200ASTP FD +α-PD -L 1α-PD-L 1P FDCo n t r o l P FD +α-P D-L 1α-PD-L 1P FDCo n tr o lBUNμm g /d l4035302520151050P FD+α-P D -L 1α-P D -L 1P FD Co nt r ol CREμm o l /L400350300250200150100500P FD+α-P D-L 1α-P D-L 1P FDCo n t r o l U /LLDH-L25020015010050图54组小鼠体质量变化及血清生化结果Fig.5Changes in body weight and blood biochemical parameters of the mice in the 4groups.A :Changes in body weight of the mice.B -F :Quantitative analysis of ALT,AST,BUN,CRE and LDH-L levels.Control PFD α-PD-L1PFD+α-PD-L1B o d y w e i g h t (g )19.519.018.518.017.517.016.516.03691215182124Days after treatment A B C D E F J South Med Univ,2024,44(2):210-216··215[17]Fujiwara A,Funaki S,Fukui E,et al.Effects of pirfenidone targetingthe tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer [J ].Sci Rep,2020,10:10900.[18]Luo DQ,Zeng XL,Zhang SL,et al.Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway [J ].J Cell Mol Med,2023,27(3):456-69.[19]Wang G,Zhou XW,Guo ZL,et al.The Anti-fibrosis drug Pirfenidonemodifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-Β[J ].Cancer Biol Ther,2022,23(1):150-62.[20]Larkin J,Chiarion-Sileni V ,Gonzalez R,et bined nivolumaband ipilimumab or monotherapy in untreated melanoma [J ].N Engl J Med,2015,373(1):23-34.[21]Robert C,Ribas A,Hamid O,et al.Three-year overall survival forpatients with advanced melanoma treated with pembrolizumab in KEYNOTE-001[J ].J Clin Oncol,2016,34(15_suppl):9503.[22]Chen DS,Mellman I.Elements of cancer immunity and the cancer-immune set point [J ].Nature,2017,541(7637):321-30.[23]Park YJ,Kuen DS,Chung Y .Future prospects of immune checkpointblockade in cancer:from response prediction to overcoming resistance [J ].Exp Mol Med,2018,50(8):130.[24]McGranahan N,Furness AJS,Rosenthal R,et al.Clonal neoantigenselicit T cell immunoreactivity and sensitivity to immune checkpoint blockade [J ].Science,2016,351(6280):1463-9.[25]Rajabi P,Neshat A,Mokhtari M,et al.The role of VEGF inmelanoma progression [J ].J Res Med Sci,2012,17(6):534-9.[26]Dong ZY ,Wu SP,Liao RQ,et al.Potential biomarker for checkpointblockade immunotherapy and treatment strategy [J ].Tumour Biol,2016,37(4):4251-61.[27]Wu WT,Wang WQ,Wang Y ,et al.IL-37b suppresses T cell primingby modulating dendritic cell maturation and cytokine production via dampening ERK/NF-κB/S6K signalings [J ].Acta Biochim Biophys Sin,2015,47(8):597-603.[28]Qian JW,Wang C,Wang B,et al.The IFN-γ/PD-L1axis between Tcells and tumor microenvironment:hints for glioma anti-PD-1/PD-L1therapy [J ].J Neuroinflammation,2018,15(1):290.[29]Liu YT,Sun ZJ.Turning cold tumors into hot tumors by improving T-cell infiltration [J ].Theranostics,2021,11(11):5365-86.[30]Reda M,Ngamcherdtrakul W,Nelson MA,et al.Development of ananoparticle-based immunotherapy targeting PD-L1and PLK1for lung cancer treatment [J ].Nat Commun,2022,13(1):4261.[31]Lee D,Huntoon K,Wang YF,et al.Harnessing innate immunityusing biomaterials for cancer immunotherapy [J ].Adv Mater,2021,33(27):e2007576.(编辑:吴锦雅)J South Med Univ,2024,44(2):210-216··216Efficacy of navel application of Jianpiwenyang Gel for chronic diarrhea of spleen and stomach weakness type:a randomized controlled trial and analysis of the mechanismCUI Yixin 1,WANG Decai 2,XIE Dongqing 3,WANG Haiming 1,XU Ruixin 1,TANG Xiaoran 1,ZHANG Yin 11Department of Traditional Chinese Medicine of the Sixth Clinical Center,3Department of Ultrasound of the First Clinical Center,Chinese PLA General Hospital,Beijing 100853,China;2Second Outpatient Department,Aerospace Center Hospital,Beijing 100049,China摘要:目的探讨健脾温阳凝胶剂(SSWYG )治疗慢性腹泻的临床疗效及作用机制。

大学英语六级改革适用(段落翻译)模拟试卷466(题后含答案及解析)

大学英语六级改革适用(段落翻译)模拟试卷466(题后含答案及解析)

大学英语六级改革适用(段落翻译)模拟试卷466(题后含答案及解析)题型有: 4. TranslationPart ⅣTranslation1.纸的发明对世界文化和国际交流是一个重大的贡献。

最早的汉字是刻在动物的骨头或乌龟壳上的。

战国时期(the Warring States Period),文字开始被刻在竹简(bamboo slips)上。

然而,骨头、竹片和木头都非常重,不便于携带。

到了西汉时期,当时的贵族(noble caste)用的是丝绸或棉花做的薄纸。

这种纸不仅便于书写,还特别适合作画。

但是其造价太高,平民百姓根本承受不起。

公元105年,东汉官员蔡伦在学习总结前人造纸方法的基础上发明了一种新型的低成本植物纤维(fiber)纸。

正确答案:The invention of paper making is a great contribution to the world’s cultural development and international communication. The earliest Chinese characters were carved on animal’s bones or tortoise’s shells. During the Warring States Period, bamboo slips were used instead. However, bones, bamboo slips and wood were too heavy to carry. During the Western Han Dynasty, the noble caste wrote on thin paper made from silk or cotton. It’s easy to write and even excellent to paint on this kind of paper. However, it was so expensive that the civilians couldn’t afford it. In 105 A. D. , Cai Lun, a high-ranking official in the Eastern Han Dynasty, learned from the old way of paper making and invented a new kind of cheap plant fiber paper.“对……是一个重大的贡献”译为a great contribution to…。

老年慢性肺源性心脏病急性加重期患者应用新活素与米力农治疗3天后的疗效与安全性对比

老年慢性肺源性心脏病急性加重期患者应用新活素与米力农治疗3天后的疗效与安全性对比

-临床研究•老年慢性肺源性心脏病急性加重期患者应用新活素与米力农治疗3天后的疗效与安全性对比王绪云打马广艳2,苏留超打谭效锋打尹彤3%C天津市天津医院普内科,天津300211;2天津市第三中心医院呼吸内科,天津300170;3解放军总医院第一医学中心心血管内科,北京100853)!摘要】目的比较新活素与米力农在治疗老年慢性肺源性心脏病(CPHD)急性加重期患者疗效与安全性的差异。

方法回顾性分析2017年1月至2019年12月天津医院及天津市第三中心医院年龄"65岁的69例CPHD急性加重期患者的临床资料。

按照接受药物治疗不同分为2组,米力农组"40例)和新活素组"29例)&比较2组患者临床疗效,治疗前、治疗后3d心率"HR) *24h尿量、脑钠肽(BNP)、血肌酹(SCr)、肺动脉收缩压(PASP)、左室射血分数(LVEF)变化及不良反应发生情况。

采用SPSS17-0软件对数据进行分析。

根据数据类型,组间比较分别采用X2检验或t检验。

结果治疗后,新活素组总有效情况优于米力农组'27(93-1%)和29(72.5%)],差异有统计学意义(X2=4.667,P=0.031)&2组患者治疗后HR、BNP、SCr、PASP较治疗前均有所降低,LVEF、24h尿量较治疗前均明显升高,差异均有统计学意义(均P<0.05);在降低BNP、PASP,提高LVEF、增加尿量方面,新活素组优于米力农组,差异均有统计学意义(均P<0.05)&米力农组患者用药后发生恶心呕吐、室性心律不齐及其他3例(7-5%),新活素组患者发生低血压2例(6-7%),差异无统计学意义(P>0.05)。

发生不良反应的患者均经调整药物剂量及对症治疗后好转,无严重不良反应发生。

结论新活素和米力农对治疗老年CPHD急性加重期患者均有明显的效果及较好的安全性,新活素比米力农的治疗效果更显著。

大学英语六级考试模拟试卷五十三(带答案)

大学英语六级考试模拟试卷五十三(带答案)

大学英语六级考试模拟试卷五十三(总分:710.00,做题时间:130分钟)翻译题(总题数:5,分数:710.00)1.中国共有8大菜系(cuisine),包括辛辣的(pungent)川菜和清淡的(light)粤菜。

中国餐馆在世界各地很受欢迎。

然而,中国人的生活方式日益变化,无论是自己下厨还是上餐馆,都出现了全新的饮食习惯。

在一些传统的中国菜中,添加了奶酪和番茄酱(cheese and tomato sauce)。

城市消费者频繁地光顾一些快餐连锁店,比如麦当劳、肯德基。

收入的不断增长,对国际食品更多的了解,加上超市购物的便捷,使中国出现了更乐于尝试包装及罐装食品(packaged and canned food)的新一代消费者。

(分数:142.00)_________________________________________________________________ _________________________正确答案:( China has 8 major cuisines, including Sichuan cuisine famous for pungency and Cantonese cuisine for lightness. Chinese restaurants enjoy great popularity all over the world. With the ever-changing of the Chinese lifestyle, however, people are experiencing a new diet style either when cooking at home or eating at restaurants. For instance, the cheese and tomato sauce are added to the traditional Chinese food, and urban consumers now frequently go to fast food chains, such as McDonald's and KFC. The steady growth of people's income, more knowledge about international food and the convenience of supermarket shopping bring to the emergence of a new generation of consumers who are more likely to buy packaged and canned food.)解析:2.近年来中国经济增长很快,而污染和排放(emission)问题也同样惊人。

尼可地尔联合曲美他嗪对冠心病病人PCI术后心功能及ADL评分的影响

尼可地尔联合曲美他嗪对冠心病病人PCI术后心功能及ADL评分的影响

单 位 :分
ADL 评分比较,差异无统计 学 意 义 (P > 0.05);治 疗 3 个月 后,两 组 ADL 评 分 均 高 于 治 疗 前,且 观 察 组 高 于 对照组,差异有统计学意义(P <0.01)。详见表 2。 2.3 两组术 后 不 良 心 血 管 事 件 发 生 率 比 较 观 察 组 术后不良心血管 事 件 发 生 率 低 于 对 照 组,差 异 有 统 计 学意义(7.89% 与 26.32% ,P <0.05)。详见表 3。
· 2062 ·
CHINESEJOURNAL OFINTEGRATIVE MEDICINE ON CARDIO-CEREBROVASCULAR DISEASE June 2021 Vol.19 No.12
心血 管 事 件 发 生 情 况,包 括 心 绞 痛、再 发 心 肌 梗 死、支 2 结 果
架内 狭 窄、心 力 衰 竭、再 入 院,计 算 不 良 心 血 管 事 件 发 2.1 两 组 治 疗 前 后 LVEF、LVEDD 和 LVESD 比 较
治疗前,LVEDD 和 LVESD 均低于治疗前,且观察组优 于对照组,差异有统计学意义(P <0.01)。详见表 1。
学意义。
表 1 两组治疗前后 LVEF、LVEDD 和 LVESD 比较(x ±s )
组别 例数
对照组 38 观察组 38 t值 P
LVEF(% )
治疗前
43.16± 5.31 43.02± 5.27
例数
心绞痛
再发心肌梗死
支架内狭窄
对照组
38
观察组
38
3(7.89) 1(2.63)
2(5.26) 1(2.63)
3(7.89) 0(0.00)

胃癌新辅助化疗前血小板水平与疗效的关系要点


and
瘤,抑制肿瘤生长;同时化疗药物能降低血小板水
平,能减少血小板对肿瘤生长转移的促进作用,间接 抑制肿瘤。
degranulation induce pro—-survival and pro・・angiogenic ovarian
cancer
sigualling in
cells[J].PLoS One,2011,6(10):e26125.
板水平能够对其疗效进行初步预测:新辅助化疗前
血小板高于正常水平的胃癌患者与血小板在正常水 平胃癌患者的新辅助治疗总体有效率分别36.8%、 69.9%,患者在新辅助化疗前血小板水平越高,新辅 助化疗总体有效率越低。同时我们认为根据血小板 水平也能预测胃癌患者术后辅助化疗的疗效。 入组患者新辅助化疗前血小板均在正常水平范 围内或高于正常水平。其中血小板高于正常水平患 者19例.血小板计数>400×109/L患者4例。新
本研究结果表明,胃癌患者在新辅助化疗前的血小
二、混杂因素分析 根据胃癌患者新辅助化疗前血小板水平分为升
高组(>300×109/L)及正常组(≤300×109/L)。 两组患者的年龄、BMI、性别、化疗周期相比差异均 无统计学意义(均P>0.05),可以排除混杂因素对 分组分析结果的影响,见表1。 三、新辅助化疗前不同血小板水平胃癌患者的 疗效 根据胃癌治疗前血小板的情况分为血小板> 300×109/L组和血小板≤300×109/L组。如表2 所示,两组患者化疗有效率分别为36.8%、69.9%, 差异有统计学意义。
J.Vasquez
ovarian HG.et a1.PIatelets
cancer
Cho MS.Bottsford.Miller
increase the proliferation of

前房冲洗在严重前房积脓性角膜溃疡的 角膜移植术中应用

查视力恢复情况等。

结果20例患者均成功行前房穿刺冲洗联合角膜移植手术并保存眼球,其中11只眼(11例真菌性角膜溃疡)接受了穿透性角膜移植,9只眼(4例细菌性角膜溃疡,5例真菌性角膜溃疡)行板层角膜移植。

11例接受穿透性角膜移植的患者中10例采用角膜中期保存液保存供体角膜,另10例患者采用甘油脱水冷冻保存供体角膜(图1)。

一、角膜刮片、培养及共焦显微镜检查结果1.角膜刮片:16例诊断为真菌性角膜炎患者中15例(94%)角膜刮片查见菌丝,角膜刮片真菌培养13例(81%)阳性,其中9例为镰刀菌,4例为曲霉菌。

4例诊断为细菌性角膜炎患者中l例(25%)角膜刮片查见革兰阴性杆菌;细菌培养3例(75%)阳性,均为铜绿假单胞菌(绿脓杆菌)。

2.细菌和真菌培养:16例诊断为真菌性角膜炎的患者于手术中取下的角膜片真菌培养14例(88%)阳性,其中10例为镰刀菌,4例为曲霉菌,角膜片细菌培养2例(诊断为真菌性角膜炎的患者)阳性,分别为葡萄球菌哑种和表皮葡萄球菌;诊断为细菌性角膜炎的患者角膜片细菌培养均为阴性。

3.共焦显微镜检查:16例诊断为真菌性角膜炎的患者中12例行共焦显微镜检查,10例(83%)查见菌丝伴有大量炎性细胞浸润;4例细菌性角膜炎患者的共焦显微镜检菌丝均为阴性,查见大量炎性细胞浸润。

二、围手术期并发症1.术中并发症:1l例患者手术过程中出现虹膜出血,手术过程中未行特殊处理,形成前房后无活动性出血。

手术中未出现暴发性脉络膜出血或眼内容物脱出者。

2.术后并发症:8例患者发生部分虹膜后粘连,5例粘连范围小于3个钟点位,3例大于3个钟点位;4例患者出现一过性眼压高,给予前房放液和局部应用0.5%噻吗洛尔眼液后逐渐缓解,手术后1个月未发现继发青光眼持续眼压高的患者。

5例患者手术后前房内见2—5mill积血,给予全身应用注射用血凝酶lU肌肉注射1次,半卧位,3—7d后4例患者积血吸收,1例患者行前房冲洗后积血清除。

抗精神病药与代谢综合征


3
4
5
6
其他处理对策
行为干预:限制进食,增加锻炼,防治肥胖 药物干预(5-HT2和H1-R阻断剂) - 厌食药物芬氟拉明:心脏毒性, 加重病情 - 新型抗抑郁药 - 抗糖尿病药物,如二甲双胍(精神科与全科联合治疗)
7
Metformin addition to attenuate olanzapineinduced weight gain in drug-naive firstepisode schizophrenia patients: a double-blind, placebo-controlled study
18
Methods
128 patients were randomized to one of four 12week individual treatments: metformin (750mg/day),n=32 placebo, n=32 LI plus metformin (750mg/day), n=32 or LI plus placebo, n=32 Medications were provided in double-blind fashion.
脂肪占<30%(饱和脂肪酸<7%),碳水化合物应占55%, 蛋白质占15%-20%,每日摄入的胆固醇在200mg以下。 纤维丰富的食物保证在15%以上。记载患者每日的进食情 况,评估患者对饮食疗法的依从性。
Exercise intervention:每天持续进行至少30分钟的
全身性有氧运动
23
All Assessments
8
Introduction
Metformin is a hepatic-selective insulin sensitizer Metformin can increase tissue sensitivity to insulin and reduce in hepatic glucose output Metformin reduces weight, blood glucose, insulin and hemoglobin Alc (HbAlc) levels in obese nondiabetic adults Metformin is not metabolized and does not inhibit the metabolism of other drugs A litter study proved efficacy The purpose was to assess the efficacy of metformin in preventing olanzapine-induced weight gain

邻苯二甲醛消毒剂杀菌效果及临床应用的研究

第18卷 第3期医学研究生学报Vol.18 No.3 2005年3月Journal of Medical Postgraduates Mar.2005・论 著・邻苯二甲醛消毒剂杀菌效果及临床应用的研究尹湘毅, 张皖瑜, 张国, 丁 艳(南京军区南京总医院感染控制科,江苏南京210002)摘要: 目的:为了解邻苯二甲醛消毒剂的杀菌效果。

 方法:采用载体定量杀菌试验及临床应用研究的方法。

 结果:邻苯二甲醛消毒剂原液在23℃条件下,作用90m in可100%杀灭载体上枯草杆菌黑色变种芽胞;作用10m in 可完全破坏血清乙型肝炎表面抗原(HB s Ag)抗原性;作用5m in可100%杀灭细菌繁殖体;连续使用10天,杀菌效果无明显变化;对碳钢、不锈钢、硅胶类等医疗器械连续浸泡14天未见腐蚀现象;对皮肤黏膜无刺激性。

 结论:邻苯二甲醛消毒剂具有良好的杀菌效果,属无腐蚀、无刺激消毒剂。

关键词: 邻苯二甲醛; 枯草杆菌黑色变种芽胞; 乙型肝炎表面抗原; 细菌繁殖体中图分类号: R187 文献标识码: A 文章编号: 100828199(2005)03202392033Study on germ icidal efficacy and cli n ical use of orthophthalal dhyde disi n fectantYI N Xiang2yi,ZHANG W an2yu,Z HANG Guo2xiu,D I N G Yan(D epart m en t of Infection Con trol,N anjing General Hospital of N anjing M ilitary Co mm and,PLA,N anjing 210002,J iangsu,Ch ina)Abstract: O bjective:I n order t o kuow the ger m icidal efficacy of orthophthalaldhyde. M ethods:Car2 rier quantitative ger m icidal test and clinical use study. R esu lts:the showed that23℃,the average kill2 ing ratc after exposure t o the st ock s oluti on of orthophthalaldhyde disinfectant for90m in was100%of Ba2 cillus Subtitis Var.niger on carriers and f or10m in contact ti m e could destr oy comp letely the antigenicity of seru m HB s Ag,and f or5m in was100%of bacteria.I ncontinuous use f or10days,i m mersi on in f or14 days it was no corr osi on of carben steel and stainless steel apparatus,and no irritative t o skin and mucous me mbrane. C onclusion:O rthophthalaldhyde has good ger m icidal efficacy and bel ongs actually no cor2 r osi on and no irritative disinfectant.Key words: O rthophthalaldhyde; Bacillus Subtitis Var.niger; HB s Ag; Bacteria0 引 言邻苯二甲醛(orthophthalaldehyde,OP A)是近年国外研究出的一种新型化学消毒剂,其性能稳定,使用浓度低,对皮肤黏膜无刺激性,无不良气味,具有戊二醛的优良杀灭微生物能力和低腐蚀等优点[1]。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Original research articleEfficacy of a new method of family planning:the StandardDays Method ૾Marcos Are ´valo,Victoria Jennings *,Irit SinaiGeorgetown University,3PHC,3800Reservoir Rd.,NW,Washington,DC 20007,USAReceived 19November 2001;received in revised form 12December 2001;accepted 12December 2001AbstractThe Standard Days Method is a fertility awareness-based method of family planning in which users avoid unprotected intercourse duringcycle Days 8through 19.A prospective multi-center efficacy trial was conducted to test,in a heterogeneous population,the contraceptive efficacy of the Standard Days Method.A total of 478women,age 18–39years,in Bolivia,Peru,and the Philippines,with self-reported cycles of 26–32days,desiring to delay pregnancy at least one year were admitted to the study.A single decrement multi-censoring life table analysis of the data indicate a cumulative probability of pregnancy of 4.75%over 13cycles of correct use of the method,and a 11.96%probability of pregnancy under typical use.This article describes the study and the results.Results suggest that despite its requirement that couples modify their sexual behavior when the woman is fertile,the Standard Days Method provides significant protection from unplanned pregnancy and is acceptable to couples in a wide range of settings.©2002Elsevier Science Inc.All rights reserved.Keywords:Standard Days Method;Contraceptive efficacy;Fertility awareness1.IntroductionA couple wanting to avoid or achieve pregnancy by timing intercourse needs to know when during her men-strual cycle the woman is most likely to become pregnant.They can do so by using a fertility awareness-based family planning method.The fertile window of the woman’s men-strual cycle consists of approximately 6days—the 5days before ovulation and the day of ovulation,with variable probabilities of pregnancy for each day [1,2].However,the timing of ovulation is variable both among women and across cycles of the same woman,with some women expe-riencing much greater variability than others [3].A fertility awareness-based method that takes into account this vari-ability could be a viable option for many couples.The Institute for Reproductive Health,Georgetown University,proposed a fixed formula in which women who typically have menstrual cycles of 26to 32days consider themselves fertile during Days 8through 19(12days)of their cycles.To prevent unplanned pregnancy,they avoid unprotected intercourse on those days [4].Ideally,a woman using a fertility awareness-based method should be able to identify the 6days of her fertile window,with neither “false positives”(i.e.,days identified as fertile that actually are infertile),nor “false negatives”(i.e.,days identified as infertile that actually are fertile)[5].The technology necessary for this degree of accuracy,how-ever,is not widely available or affordable,especially in developing countries.Balancing the need to provide effec-tive protection from unplanned pregnancy while restricting the identified fertile period to as few days as possible,we developed the Standard Days Method (SDM),in which a woman considers herself potentially fertile on Days 8through 19of her menstrual cycle.If she does not want to become pregnant,she avoids unprotected intercourse on those days.To develop the SDM,we applied various formulae (i.e.,various numbers of days and various sets of days)to over 7500menstrual cycles in an existing data set from the World Health Organization (WHO)[6].The goal was to determine which formula provided the best balance between૾Support for conceptualizing the SDM,implementing the effective-ness study,and preparing this article was provided by the Institute for Reproductive Health,Department of Obstetrics and Gynecology at George-town University,Washington,DC,which is funded under a cooperative agreement HRN-A-00-97-00011-00 with the United States Agency for International Development (USAID).*Corresponding author.Tel.:ϩ1-202-687-1392;fax:ϩ1-202-687-6846.E-mail address:jenningv@ (V.Jennings).Contraception 65(2002)333–3380010-7824/02/$–see front matter ©2002Elsevier Science Inc.All rights reserved.PII:S0010-7824(02)00288-3length of the identified fertile period and efficacy in avoid-ing unplanned pregnancy.To accomplish this,we devel-oped a computer simulation that took into account the vari-able probability of pregnancy on different cycle days before and including the probable day of ovulation as well as the variable probability of ovulation occurring on different cy-cle days.1The8through19formula provided maximum protection while minimizing the number of days of avoiding unprotected intercourse.We estimated that if women with cycles ranging26to32days had used the8through19 formula and avoided unprotected intercourse on those days, the highest probability of pregnancy on any given day was only0.007.We then estimated that the method would be almost as effective for women who typically have cycles within the26 through32day range but occasionally(no more than twice in a12-month period)have a shorter or longer cycle.How-ever,the8through19formula would be less effective for women who consistently have cycles shorter than26days or longer than32days.Nonetheless,even when all women and all cycles regardless of length were included in the com-puter simulation,the highest probability of pregnancy/inter-course on any given day was still only0.011.In designing this efficacy study,we followed the guide-lines recommended by Trussell and Kost[7].Data collec-tion instruments,participant enrollment,and pregnancy def-inition were all influenced by those recommendations.Their guidelines also affected the way we analyzed the data and, thus the results presented in this article.2.Materials and methodsA prospective,non-randomized,multi-center study to test the efficacy of the SDM was conducted among cultur-ally diverse populations.Participants were enrolled from five sites in Bolivia(Trinidad),Peru(Juliaca and Lima),and the Philippines(La Trinidad and Tuba).2.1.Study participantsA total of478women(married or living with a stable partner)were admitted to the study.All participants were between18and39years old(to minimize cycle variability and subfertility),had regular menstrual cycles(defined as recent history of most cycles between26and32days long, as determined by a screening protocol),were willing to avoid intercourse12consecutive days every cycle,and had partners willing to collaborate.Potential participants were screened for subfecundity,risk of sexually transmitted dis-eases,and contraindications of pregnancy.2.2.ProceduresIn all sites,the Institute for Reproductive Health trained 5to10health workers(service providers)in the SDM and in study procedures.Method provision involved a counsel-ing session in which the woman(or the couple,if her partner was available)was instructed in the SDM,and counseled on the importance of following the method recommendations to avoid pregnancy.She was invited to contact the provider with questions and to include her partner in any subsequent contact,as appropriate.To assist women in monitoring their cycles,the provider gave them a mnemonic device,a string of32beads in which each bead represents a day of the menstrual cycle.Thefirst bead is red,representing thefirst day of menses;the next6beads are brown,representing the additional non-fertile days preceding the fertile window;the next12beads are white,representing days that should be considered fertile(8–19);and the remaining13beads are brown,again representing non-fertile days.The bead assem-bly also has a moveable,tight-fitting rubber ring that is used to mark the current day of the cycle.Women were instructed to place the ring on the red bead on the day their menses began and to move the ring one bead per day until their menses returned.They also were told that to avoid preg-nancy,they should not have unprotected intercourse on the days the ring was on a white bead.If they had menstrual bleeding before Day27of the cycle(i.e.,a cycle shorter than26days),or if their menses had not occurred by the day after they completed all32beads(i.e.,a cycle longer than 32days),they were instructed to contact their provider for further assessment and advice.Women who had two cycles outside the26through32day range during the study period were advised to use another method and were withdrawn from the study.2The mnemonic device,called CycleBeads, and its instructions are shown in Fig.1.Providers also were trained to collect the data needed for the study.The protocol,data collection instruments and consent form were approved by the Georgetown University Medical Center Institutional Review Board.Written,in-formed consent was obtained from all study participants.In addition to using the CycleBeads to monitor their cycle days,for study purposes participants also marked the first day of their menses on a calendar and kept a coital log in which they also indicated the days they used another method(i.e.,condom or withdrawal).Women in the study were interviewed each cycle,until they either completed13 cycles or left the study for other reasons.During each interview,the interviewer reviewed the woman’s completed coital log,checked the cycle day indicated on the calendar with the position of the ring on the CycleBeads,determined whether she continued to use the method(including reason for discontinuation,if applicable),and screened for possible pregnancy.Women who had not had their menses by Day 42of their cycle were tested for pregnancy.If results were negative,they were followed until they tested positive or their menses returned.They were then exited from the study because of extremely irregular cycle length.Loss to fol-low-up was minimized by interviewing study participants in their homes and actively seeking out each participant,with a minimum of three attempts per cycle.334M.Are´valo et al./Contraception65(2002)333–3382.3.AnalysisWe used single-decrement multi-censoring life tables.Multi-censoring life tables allowed us to exclude some cycles from the analysis without censoring the woman con-tributing the cycles from the rest of the study [8].We excluded cycles during which the participant did not have intercourse (0.35%)because there was no exposure to the risk of pregnancy.We also excluded cycles during which another method of family planning was used on days other than 8through 19,which are identi fied as non-fertile by the SDM.These cycles were excluded because it is not possible to determine whether the woman was protected from preg-nancy by the SDM only or by the other method.3.ResultsA total of 478women were admitted into the trial,with a mean age of 29.4years.Women in the study were drawn from urban,mixed urban/rural and rural sites.Lima was the largest city;study participants from La Trinidad (the Phil-ippines),Trinidad (Bolivia),and Juliaca (Peru)lived in a variety of mixed urban/rural settings in these smaller cities;Tuba (the Philippines)was a rural site.Participants ’educational levels were relatively high:more than 90%of women had completed primary educa-tion.When asked to read simple instructions related to the method,only 9%of women either could not read them or had dif ficulty completing the task.Almost all (98.9%)study participants had children,with a mean of 2.5children per woman.Most participants had at least one child 2years old or younger.As would be ex-pected given the communities where they lived,almost 80%of study participants stated they were Catholic,although only one woman mentioned her religious beliefs as a factor in her choice of method.There was signi ficant variability among the sites with regard to previous use of family planning.Women living in more urban areas had more experience with hormonal con-traceptives and intrauterine devices,while traditional meth-ods were more common in rural areas.Although one-third of women were breastfeeding at admission,they met all study criteria,including having experienced at leastthreeFig.1.CycleBeads and instructions for use.335M.Are ´valo et al./Contraception 65(2002)333–338regular cycles since the last birth.Almost half of study participants received an income from work outside the home.The client profile is shown in Table1.Of all women who entered the study,46%completed13 cycles of method use.Of those who did not complete13 cycles,the largest group(28%of the total sample)corre-sponds to those who,following the study protocol,were removed from the study after they had two cycles outside the26through32day range(including13women errone-ously exited after a single such cycle)or experienced a single cycle longer than42days.Throughout13cycles of method use,very few women(4%)left the study because they or their partner did not like or trust the method.Rea-sons for leaving the study are presented in Table2.A total of4035cycles were contributed by the478study participants.Correct method use(no intercourse on Days 8–19)was reported in92%of cycles.In an additional5%of cycles,intercourse did occur,but with use of another method(condom or withdrawal).Unprotected intercourse occurred in only3%of cycles.A total of only43pregnan-cies occurred during the study.Predictably,most(65%)of the pregnancies occurred during cycles in which the woman reported unprotected intercourse during Days8through19 (days identified as fertile by the method).Only15study participants became pregnant in cycles in which no inter-course was reported during Days8–19.Most pregnancies occurred during thefirst cycles of method use(42%of all pregnancies occurred in thefirst three cycles)and very few in the latter cycles(only three pregnancies in the lastfive cycles).Thefirst-year pregnancy rate was4.8(95%;CI2.33–7.11)with correct use of the method(pregnancies occurring in cycles in which participants reported no intercourse on Days8–19).When we include cycles in which women reported intercourse with use of condom or withdrawal during their fertile days,thefirst-year pregnancy rate is slightly higher(5.7%;CI3.11–8.16).A1-year pregnancy rate of12(CI8.47–15.33)was calculated when taking into account all cycles and all pregnancies.The single-decrement multi-censoring life table for cor-rect use(including only cycles and only pregnancies with no intercourse on Days8–19)is presented in Table3.The life table for all cycles is presented in Table4.4.DiscussionWith only43women of478in our study becoming pregnant,it appears that the SDM is effective in preventing unplanned pregnancies.As shown in Table5,efficacy of the SDM is comparable to that of male condoms and is signif-icantly better than that of other barrier methods(female condom,diaphragm,cervical cap,or spermicides)[9].Thefinding that the method was used correctly in most cycles(i.e.that couples avoided unprotected intercourse during the entire fertile period as identified by the method)Table1Profile of participants in the Standard Days Method efficacy study(nϭ478)Characteristic Percent ofparticipants Study siteTrinidad,Bolivia11.5 Juliaca,Peru21.3 Lima,Peru21.1La Trinidad,Philippines21.3 Tuba,Philippines24.7Age at admission18–2423.525–2925.630–3429.435–3921.4 ParityNo children 1.11–2children58.33–4children32.15children or more8.5 EducationCompleted primary education or lower14.9 Some secondary education or higher85.1 OccupationNo income earning occupation51.9 Agriculture 5.5 Sales18.3Blue collar job15.3 White collar job8.9Ever use of family planning methods aNone9.6 Calendar55.9 Withdrawal37.0 Lactational Amenorreah(LAM) 1.3 Other natural methods 2.7 Barrier method30.8Intra Uterine Device12.8 Hormonal method30.0a Figures add to more than100%because many respondents specified more than one method.Table2Reason for exiting from Standard Days Method efficacy study(nϭ478)Reason for exit Percent ofparticipants Completed13cycles45.6Had2cycles out of the26–32-day range a28.0Was told that a pregnancy would be high risk0.2 Client did not like the method0.2 Client did not trust the method 1.7 Partner did not like the method 2.1 Wanted to get pregnant 2.1 Exited for another voluntary reason 4.0Lost to follow-up7.1 Pregnant9.0a Includes also25clients who exited after just one cycle out of range.Of these,12clients had a cycle42days or longer,and13clients exited early because of an error.336M.Are´valo et al./Contraception65(2002)333–338suggests that those couples admitted into the study were able to understand the method and were capable of trans-lating the method’s recommendation into behavior consis-tent with their expressed reproductive intention.Couples participating in the study seemed no more or no less sexu-ally active than the general population.They reported an average of5.5acts of intercourse per cycle.Thisfigure is similar to the64yearly(5.3monthly)acts of intercourse reported for users of coitus-dependent methods in32coun-tries throughout the world[10].Almost all study participants were literate(91%were able to read simple method instructions).No reliablefigures are available about schooling in study localities;however, study participants had more years of formal education than their respective national averages.Participants in the SDM trial are very different from the population of a recent study by Wilcox et al.,which re-ported ovulation as early as cycle Day8or as late as cycle Day60.Unlike SDM trial participants,participants in the Wilcox study were neither screened for cycle length before admission to the study nor withdrawn because of cycle length variations(they reported usual cycle lengths from19 to60days)[3].Many of them clearly would not be eligible to use the SDM.In designing this study,we were careful to adhere to the criteria for contraceptive efficacy studies defined by Trussell and Kost[7].Thus,our sample included only women who were likely to be fecund and exposed to the risk of pregnancy.Defining the reason(s)for discontinuation and identifying and reporting early pregnancies detected by lab-oratory tests also are important.Pregnancies were identified at42days post LMP;women who tested negative for preg-nancy but who were still amenorrheic were followed until they either menstruated or tested positive for pregnancy.Most efficacy studies of fertility awareness-based family planning methods do not actually enroll women into the study until they have completed a“learning phase,”typi-cally a three-month period during which they receive in-struction in the method[11,12].Pregnancy rates in those studies are artificially reduced if the analysis excludes the early cycles of use.In this study,we included women beginning with theirfirst cycle of use.As previously noted, most pregnancies occurred in earlier cycles.A weakness of the study was reliance on women’s self-reported intercourse and other method use.We expect that women may have under-reported intercourse,especially on Days8through19,and that they may have used other methods(barrier or withdrawal)more frequently than re-ported.Because the collection of information on intercourse relied on self-reporting,we have no way of confirming the extent of this under-reporting.Another weakness is that the monthly follow-up schedule,while necessary for data col-lection,may have increased correct use of the method.Additional questions about the SDM will be addressed inTable3Life table pregnancy rates for correct use of the standard days methodCycle Womenexposed a Pregnancies Pregnancyrate95%confidenceinterval137310.270.00to0.79 238420.790.00to1.67 33613 1.610.32to2.89 43422 2.190.68to3.68 53170 2.190.68to3.68 62974 3.51 1.53to5.45 72640 3.51 1.53to5.45 82442 4.30 2.04to6.50 92420 4.30 2.04to6.50 102230 4.30 2.04to6.50 112250 4.30 2.04to6.50 122150 4.30 2.04to6.50 132151 4.75 2.33to7.11 a Excluding censored cycles.Table4Life table pregnancy rates including correct and incorrect use of the standard days methodCycle Womenexposed a Pregnancies Pregnancyrate95%confidenceinterval14525 1.110.14to2.07 24365 2.240.86to3.60 33958 4.22 2.29to6.11 43635 5.54 3.31to7.72 53405 6.93 4.41to9.38 630868.74 5.87to11.53 728029.39 6.39to12.30 8262410.787.52to13.92 9252010.787.52to13.92 10236111.167.82to14.37 11230011.167.82to14.37 12220111.568.14to14.85 13218111.968.47to15.33 a Excluding censored cycles.Table5Rates of unintended pregnancy during thefirst year of typical use and thefirst year of perfect use of user-dependent family planning methods a and the standard days methodMethod b Pregnancy rateTypical use Correct use Chance8585 Spermicides266CapParous women4026 Nulliparous women209 Diaphragm206 CondomMale143 Female215 Standard Days Method125a Source:Hatcher et al.[9].b Thesefigures are drawn from studies using different methodologies, and,therefore,may not be directly comparable.337M.Are´valo et al./Contraception65(2002)333–338forthcoming articles,drawing on both additional analysis of the efficacy trial data and from other ongoing research. 5.ConclusionThis efficacy trial demonstrated that the SDM is an effective method of family planning.With afirst year preg-nancy rate of less than5%with correct use,it is comparable to other user-controlled methods currently available through reproductive health and other programs.The study also has shown that clients are able to learn the method and to use it successfully to avoid unplanned pregnancy.The SDM of-fers a valuable addition to the services that reproductive health and other programs can offer.Because it is simple to teach,learn and use,the SDM also has the potential to be provided outside the context of traditional family planning programs,through community development,non-govern-mental,and social marketing organizations.Operations re-search studies are ongoing to address some of these issues and explore how best to provide the SDM in these and other settings.Notes1.We used Peak day as a proxy for ovulation.Peak dayis defined in the Ovulation Method as the last day ina given menstrual cycle on which fertile-type mucusis recognized,or the last day on which the wet orlubricative sensation is felt at the vulva.2.For ethical reasons,we referred these women foranother method because the theoretical protectionconferred by Standard Days Method is slightly lessfor women who consistently have cycles outside the26through32days range[4].Although it was ex-plained to them that they were more likely to becomepregnant if they continued using the SDM,many ofthem continued to do so.A further study of thesewomen is ongoing.AcknowledgmentsThe authors are particularly grateful to ourfield collab-orators:Dr.Saleg Eid,Catholic Relief Services,Bolivia;Dr. German Coaguila and Pilar Lacerna of Centro de Informa-cion Educacion y Servicios,Bolivia;Dr.Irma Ramos, CARE,Peru;Beth Yeager,Instituto de Investigacion Nu-tricional,Peru;and Betty Toledo and Mitos Rivera,Institute for Reproductive Health,Philippines.The Department of Health in Benguet,Philippines,the Ministry of Health in Juliaca,Peru,as well as the providers,researchers,and clients in all study sites made invaluable contributions to this effort.Our special thanks to Drs.James Gribble and James Shelton for their valuable suggestions in the prepa-ration of this article.The views expressed by the authors do not necessarily reflect the views or policies of USAID or Georgetown University.The Standard Days Method and CycleBeads are trademarks owned by the Georgetown University Institute for Reproductive Health.CycleBeads are U.S.patent pend-ing.References[1]Wilcox AJ,Weinberg CR,Baird DD.Timing of sexual intercourse inrelation to ovulation.N Engl J Med1995;333:1517–21.[2]Wilcox AJ,Weinberg CR,Baird DD.Post-ovulatory aging of thehuman oocyte and embryo failure.Hum Reprod1998;13:394–7. [3]Wilcox AJ,Dunson,D,Baird DD.The timing of the“fertile window”in the menstrual cycle:day specific estimates from a prospective study.Brit Med J2000;321:1259–62.[4]Are´valo M,Sinai I,Jennings V.Afixed formula to define the fertilewindow of the menstrual cycle as the basis of a simple method of Natural Family Planning.Contraception1999;60:357–60.[5]Spieler JM,Collins WP.Potential fertility—defining the window ofopportunity.J Intl Med Res2001;29(Suppl.1):3A–13A.[6]World Health Organization(WHO).A prospective multicentre trial ofthe ovulation method of natural family planning.II.The effectiveness phase.Fert Ster1981;36:591–8.[7]Trussel J,Kost K.Contraceptive failure in the United States:a criticalreview of the literature.Stud Fam Plan1987;18:237–83.[8]Kazi A,Kennedy KI,Visness CM,Khan T.Effectiveness of theLactational Amenorrhea Method in Pakistan.Fert and Steril1995;64: 717–23.[9]Hatcher RA Trussell J,Stewart F,et al.Contraceptive technology.17th ed.New York:Ardent,1998;800:Table31–1.[10]Stover J,Bertrand J,Smith S,et al.Empirically based conversionfactors for calculating couple-years of protection.Carolina Population Center2001:32.[11]Gray RH,Kambic RT,Lanctot CA,Martin MC,Wesley R,CreminsR.Evaluation of natural family planning programmes in Liberia and Zambia.J Biosoc Sci1993;25:249–58.[12]World Health Organization(WHO).A prospective multicentre trial ofthe ovulation method of natural family planning.I.The teaching phase.Fertil Steril1981;36:152–8.338M.Are´valo et al./Contraception65(2002)333–338。

相关文档
最新文档